



# **Circulating CD4<sup>+</sup>CD28<sup>null</sup> T cells and its Association with Atherosclerotic Changes in Patients with End Stage Renal Disease**

**Thesis**

*Submitted for partial fulfillment of MD Degree  
in Internal Medicine*

**By**

**Nelly Nader Gendy**

*M.Sc Internal Medicine, Faculty of Medicine,  
Ain Shams University*

**Supervised by**

**Professor/Ashraf Mahmoud Okba**

*Professor of Internal Medicine and Head of Internal Medicine  
Department*

*Head of Allergy and Clinical Immunology Department  
Faculty of Medicine, Ain Shams University*

**Professor/Mannar Abd El Raouf Raafat**

*Professor of Internal Medicine and Nephrology  
Theodor Bilharz Research Institute*

**Professor/Mohamed Nazmy Farres**

*Professor of Internal Medicine, Allergy and Clinical Immunology  
Faculty of Medicine, Ain Shams University*

**Dr/Nermine Abd El Nour Melek**

*Assistant Professor of Internal Medicine, Allergy and Clinical  
Immunology*

*Faculty of Medicine, Ain Shams University*

**Dr/Mariam Maged Amin**

*Lecturer of Internal Medicine, Allergy and Clinical Immunology  
Faculty of Medicine, Ain Shams University*

*Faculty of Medicine  
Ain Shams University*

2019

## Acknowledgment

### "First and Foremost , Thanks are Due to GOD"

I would like to express my deepest gratitude and sincere thanks to **Professor Ashraf Mahmoud Okba**, Professor of Internal Medicine and Head of Internal Medicine Department, Head of Allergy and Clinical Immunology Department, Faculty of Medicine Ain Shams University , for his instructive supervision ,continuous guidance, valuable instructions throughout the work.

I wish to express my tender thanks and deepest gratitude towards **Professor Mannar Abdel Raouf Raafat**, Professor of Internal Medicine and Nephrology, Theodor Bilharz Research Institute, for her continuous guidance, valuable suggestions, unlimited help.

Whatever I say or write, I will never be able to express my deep feelings and profound gratitude to **Professor Mohamed Nazmy Fares**, Professor of Internal Medicine, Allergy and Clinical Immunology, Faculty of Medicine, Ain Shams University for suggesting and planning the design of the work, offering all facilities for the work , instructive supervision and valuable instructions .

I am greatly indebted to **Dr. Nermine Abd El Nour Melek** , Assisstant Professor of Internal Medicine , Allergy and Clinical Immunology, Faculty of Medicine, Ain Shams University, for her instructive guidance , continuous support , advice and repetitive revision of the manuscript.

My particular sincere thanks and profound gratitude are due to **Dr. Mariam Maged Amin**, Lecturer of Internal Medicine

---

, Allergy and Clinical Immunology, Faculty of Medicine, Ain Shams University, for her continuous guidance , advice , extreme cooperation , tremendous help ,support and repetitive revision of the manuscript.

I am extremely grateful to **Professor Amna Ahmed Metwally** Professor of Intensive Care Unit and Head of Intensive Care Unit , Theodor Bilharz Research Institute for her unlimited efforts in the carotid duplex examination , she gave me much of her time, advise and effort throughout this work.

Many thanks to **Dr. Omar Mohamed Sabry**, Assisstant Professor in Hematology and Blood Bank Department, Theodor Bilharz Research Institute, for his continuous guidance, advice, extreme cooperation and tremendous help and support.

In fact, I owe much to my colleagues and the staff members of Nephrology Department, Theodor Bilharz Research Institute, for their kind help and support.

I express my deepest gratitude to my family for their extended love, care and support.

**Nelly Nader Gendy**

---

---

## List of Contents

	Page
List of abbreviations	i
List of tables	vi
List of figures	vii
Introduction	1
Aim of the study	3
Review of literature	
Chapter one : End Stage Renal Disease	4
Chapter two : Atherosclerosis	18
Chapter three : CD4 <sup>+</sup> CD28 <sup>null</sup> T cells	32
Subjects and Methods	45
Results	51
Discussion	63
Summary	75
Conclusion	77
Recommendations	78
References	79
Arabic Summary	104

---

### **List of Abbreviations**

<b>Abbreviation</b>	<b>Full term</b>
<b>AAA</b>	: Abdominal Aortic Aneurysm
<b>ACAT</b>	: Acyl-CoA: Cholesterol O-Acyltransferase
<b>ACE</b>	: Angiotensin-Converting-Enzyme
<b>ACE-Is</b>	: Angiotensin Converting Enzyme Inhibitors
<b>ACS</b>	: Acute Coronary Syndrome
<b>AIDS</b>	: Acquired Immune Deficiency Syndrome
<b>AKI</b>	: Acute Kidney Injury
<b>AMPK</b>	: Adenosine Monophosphate -Activated Protein Kinase
<b>APCs</b>	: Antigen-Presenting Cells
<b>APD</b>	: Automated Peritoneal Dialysis
<b>API</b>	: Analytical Profile Index
<b>APO</b>	: Apolipoprotein
<b>ARBs</b>	: Angiotensin Receptor Blockers
<b>ATP</b>	: Adenosine Triphosphate
<b>AUC</b>	: Area Under The Curve
<b>BCL-6</b>	: B-Cell Lymphoma 6 Protein
<b>BUN</b>	: Blood Urea Nitrogen
<b>CAC</b>	: Coronary Artery Calcium

<b>CAD</b>	: Coronary Artery Disease
<b>CAPD</b>	: Continuous Ambulatory Peritoneal Dialysis
<b>CCR</b>	: C-C Motif Chemokine Receptor
<b>CETP</b>	: Cholesteryl Ester Transfer Protein
<b>CIMT</b>	: Carotid Intima Media Thickness
<b>CKD</b>	: Chronic Kidney Disease
<b>CK-MB</b>	: Creatine Kinase-Muscle/Brain
<b>CMV</b>	: Cytomegalovirus
<b>COX2</b>	: Cyclooxygenase-2
<b>CRP</b>	: C-Reactive Protein
<b>CRRT</b>	: Continuous Renal Replacement Therapy
<b>CT</b>	: Computerized Tomography
<b>CTLA-4</b>	: Cytotoxic T-Lymphocyte-Associated Protein4
<b>CTLs</b>	: Cytotoxic T Cells
<b>CV</b>	: Cardiovascular
<b>CVD</b>	: Cardiovascular Diseases
<b>CVVH</b>	: Continuous Veno-Venous Hemofiltration
<b>CVVHD</b>	: Continuous Veno-Venous Hemodialysis
<b>CVVHDF</b>	: Continous Venovenous Hemodiafiltration
<b>CX3CR</b>	: C-X-C Chemokine Receptor

---

<b>DC</b>	: Dendritic Cells
<b>DGAT</b>	: Diacyl glycerol acyl transferase
<b>DNA</b>	: Deoxyribo nucleic Acid
<b>ECG</b>	: Electrocardiogram
<b>eGFR</b>	: Estimated Glomerular Filtration Rate
<b>ELISA</b>	: Enzyme-linked immunosorbent assay
<b>ERK1/2</b>	: Extracellular Signal-Regulated Kinase 1/2
<b>ESRD</b>	: End-Stage Renal Disease
<b>FAs</b>	: Fatty Acids
<b>Fas-FasL</b>	: First Apoptosis Signal - First Apoptosis Signal Ligand
<b>FOXP3<sup>+</sup></b>	: Forkhead Box P3
<b>GATA3</b>	: Gata-Binding Protein 3
<b>HbA1c</b>	: Hemoglobin A1c
<b>HD</b>	: Hemodialysis
<b>HDL</b>	: High Density Lipoprotein
<b>HIV</b>	: Human Immunodeficiency Virus
<b>HMG-CoA</b>	: 3-Hydroxy-3-Methyl-Glutaryl coenzyme A
<b>ICAM-1</b>	: Intercellular Adhesion Molecule-1
<b>IFN</b>	: Interferon

---

<b>IL-2R</b>	: Interleukin-2 Receptor
<b>ILs</b>	: Interleukins
<b>iNOS</b>	: Inducible Nitric Oxide Synthase
<b>IVUS</b>	: Intravascular Ultrasound
<b>KDIGO</b>	: Kidney Disease: Improving Global Outcomes
<b>KDOQI</b>	: Kidney Disease Outcomes Quality Initiative
<b>KIR2DS2</b>	: Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Short Cytoplasmic Tail 2
<b>Lck</b>	: Lymphocyte-Specific Protein Tyrosine Kinase
<b>LDL</b>	: Low Density Lipoprotein
<b>LFA-1</b>	: Leukocyte Function-Associated Antigen-1
<b>LPL</b>	: Lipoprotein Lipase
<b>MDRD</b>	: Modification Of Diet In Renal Disease
<b>MHC</b>	: Major Histocompatibility Complex
<b>MMPS</b>	: Matrix Metalloproteinases
<b>MRA</b>	: Magnetic Resonance Angiography
<b>MRI</b>	: Magnetic Resonance Imaging
<b>MS</b>	: Multiple Sclerosis
<b>MTHFR</b>	: Methylenetetrahydrofolate Reductase

---



<b>MTTP</b>	: Microsomal Triglyceride Transfer Protein
<b>NA</b>	: Not Applicable
<b>NFAT</b>	: Nuclear Factor Of Activated TCells
<b>NK</b>	: Natural Killer
<b>NKG2D</b>	: Natural-Killer Group 2, Member D
<b>NO</b>	: Nitric Oxide
<b>NOS</b>	: Nitric Oxide Synthase
<b>NSAIDs</b>	: Non Steroidal Anti- Inflammatory Drugs
<b>PAD</b>	: Peripheral Arterial Disease
<b>PBMCs</b>	: Blood mononuclear cells
<b>PBS</b>	: Phosphate buffered saline
<b>PCSK-9</b>	: Proprotein Convertase Subtilisin/Kexin Type-9
<b>PD</b>	: Peritoneal Dialysis
<b>PE</b>	: Phycoerythrin
<b>PKC-8</b>	: Protein Kinase C-8
<b>PLC-<math>\gamma</math></b>	: Phospholipase C-Gamma
<b>pmp</b>	: Patients Per Million
<b>PPAR<math>\alpha</math></b>	: Peroxisome Proliferator-Activated Receptor Alpha
<b>PPAR<math>\gamma</math></b>	: Peroxisome Proliferator-Activated Receptor Gamma

---

<b>PV-</b>	: Predictive Value Of Negative Test
<b>PV+</b>	: Predictive Value Of Positive Test
<b>RA</b>	: Rheumatoid Arthritis
<b>RAAS</b>	: Renin-Angiotensin-Aldosterone System
<b>ROC</b>	: Receiver-Operating Characteristic
<b>ROR<sub>γ</sub>T</b>	: Related Orphan Receptor GammaT
<b>RRT</b>	: Renal Replacement Therapy
<b>SCUF</b>	: Slow Continuous Ultrafiltration
<b>SD</b>	: Standard Deviation
<b>SLEDD</b>	: Sustained Low Efficiency Daily Dialysis
<b>SLEDD-F</b>	: Sustained Low Efficiency Daily Diafiltration
<b>SMCs</b>	: Smooth Muscle Cells
<b>sPLA<sub>2</sub></b>	: secreted PhosphoLipaseA2
<b>TCR</b>	: T Cell Receptor
<b>TFH</b>	: Transcriptional regulation of follicular T-helper cells
<b>TG</b>	: Triglycerides
<b>TGFbeta</b>	: Transforming Growth Factor Beta
<b>Th</b>	: T helper
<b>TIA</b>	: Transient Ischemic Attack
<b>TLRs</b>	: Toll-Like Receptors

---

<b>TNF-<math>\alpha</math></b>	: Tumor Necrosis Factor-Alpha
<b>T<sub>reg</sub></b>	: T Regulatory
<b>US</b>	: Ultrasound
<b>VCAM-1</b>	: Vascular Cell Adhesion Molecule1
<b><math>\gamma\delta</math> T cells</b>	: Gamma Delta T Cells

---

## List of Tables

Table Number	Title	Page
<b>List of tables of review, subjects and methods</b>		
1	Normal values for CIMT according to age	49
<b>List of tables of results</b>		
1	Characteristics of the three studied groups	52
2	CD4 <sup>+</sup> CD28 <sup>null</sup> T cells frequency in patients and control subjects	54
3	CD4 <sup>+</sup> CD28 <sup>null</sup> T cells percentage in the three studied groups	56
4	Receiver operating characteristic (ROC) curve analysis for discrimination between ESRD patients with or without atherosclerotic changes using CD4 <sup>+</sup> CD28 <sup>null</sup> T cells count	58

## List of Figures

Figure Number	Title	Page
<b>List of figures of review, subjects and methods</b>		
1	Pathogenesis of ESRD	6
2	Complications of end stage renal disease	9
3	Stages of development of atherosclerosis	19
4	Complications of atherosclerosis	26
5	T cell activation and T cell subsets differentiation	34
6	Phenotypic and functional features of CD4 <sup>+</sup> CD28 <sup>null</sup> T cells and their CD28 <sup>+</sup> counterparts	39

<b>Figure Number</b>	<b>Title</b>	<b>Page</b>
<b>List of figures of the results</b>		
1	Mean CD4 <sup>+</sup> CD28 <sup>null</sup> T cell frequency in participants with or without ESRD	55
2	Mean CD4 <sup>+</sup> CD28 <sup>null</sup> T cell percentage in the three studied groups	57
3	Receiver operating characteristic (ROC) curve analysis for discrimination between ESRD patients with or without atherosclerotic changes using CD4 <sup>+</sup> CD28 <sup>null</sup> T cells count	59
4	Correlation between CD4 <sup>+</sup> CD28 <sup>null</sup> T cells frequency and CRP	60
5	Correlation between CIMT and CRP	61
6	Correlation between CD4 <sup>+</sup> CD28 <sup>null</sup> T cells frequency and CIMT	62

## Introduction

Chronic kidney disease (CKD) is an increasing health problem, approximately 15% of the adults in industrialized countries suffer from CKD(*Chadban et al., 2003*).

Patients with ESRD (End Stage Renal Disease), including those on hemodialysis (HD) have increased mortality risk , especially from cardiovascular disease (CVD).This high CV risk is not only explained by conventional risk factors like hypertension, diabetes in addition to dyslipidemia(*Chiu and Mehrotra,2010*). Carotid intima- media thickness(CIMT) is a simple ,easy beside a cost-effective method for assessing atherosclerosis in addition to cardiovascular risk in adults(*Casella et al.,2008*).

Inflammatory pathway activation mediates some of the associations between renal dysfunction in addition to CV risk. Inflammatory markers, as C-reactive protein (CRP), interleukin (IL)-6, fibrinogen together with soluble adhesion molecules and cytomegalovirus(CMV)infection may have a role in CV risk in the general population especially in ESRD patients(*Ridker et al,2000;Yilmaz et al, 2005; Rao et al,2006*).

Observations suggested a role for T cells in atherosclerosis predisposition and CVD. CD4<sup>+</sup> T helper cells can augment atherogenesis(*Gerli et al,2004*).